文献速递临床试验与 GCP

替奈普酶桥接取栓治疗4.5至24小时基底动脉闭塞的随机临床试验

Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-09-23

ATTENTION LATE试验在中国40家卒中中心纳入330例发病4.5至24小时的基底动脉闭塞患者,随机接受替奈普酶静脉溶栓后取栓或单纯取栓。两组90天功能独立比例均为30%,症状性颅内出血和死亡率无显著差异,提示取栓前加用替奈普酶未改善功能结局。

要点

  • 发病4.5至24小时基底动脉闭塞患者,取栓前静脉替奈普酶未提高90天功能独立率。
  • 替奈普酶组与单纯取栓组90天功能独立率均为30%,调整率比0.92。
  • 两组症状性颅内出血和90天死亡率相似,安全性未见显著差异。

核心结论

  • 对于直接就诊于取栓能力中心的发病4.5至24小时中重度基底动脉闭塞患者,取栓前静脉给予替奈普酶未改善90天功能结局。

研究设计与样本

  • 多中心、开放标签、盲法终点随机临床试验,在中国40家卒中中心开展。
  • 2023年3月16日至2025年2月4日纳入330例发病4.5至24小时、NIHSS评分≥10的中重度基底动脉闭塞患者。
  • 患者按1:1随机接受静脉替奈普酶(0.25 mg/kg,最大25 mg)后取栓(n=166)或单纯取栓(n=164)。

主要发现

  • 替奈普酶联合取栓组50/165(30%)与单纯取栓组50/164(30%)达到90天功能独立,调整率比0.92(95%CI 0.67至1.25),风险差-0.18%(95%CI -10.13%至9.76%)。
  • 症状性颅内出血在替奈普酶联合取栓组发生8例(5%),单纯取栓组6例(4%)。
  • 90天死亡率两组相似,分别为66例(40%)和70例(43%)。

临床怎么用

  • 发病4.5至24小时的中重度基底动脉闭塞患者直接送至取栓中心时,取栓前加用静脉替奈普酶未显示额外获益。
  • 临床决策应综合考虑患者个体情况,不能仅依据本试验结果推广至未直接就诊于取栓中心的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether intravenous tenecteplase before endovascular thrombectomy (EVT) improves outcomes in patients with basilar artery occlusion presenting 4.5 to 24 hours after stroke onset remains uncertain. OBJECTIVE: To evaluate the efficacy and safety of intravenous tenecteplase before EVT vs EVT alone in patients with moderate to severe basilar artery occlusion admitted within 4.5 to 24 hours from stroke onset. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded end point, randomized clinical trial was conducted at 40 stroke centers in China. Between March 16, 2023, and February 4, 2025, a total of 330 patients with moderate to severe basilar artery occlusion (National Institutes of Health Stroke Scale score ≥10) presenting within 4.5 to 24 hours from stroke onset to EVT-capable centers were enrolled. Final follow-up was completed on May 4, 2025. INTERVENTIONS: Patients were randomized 1:1 via a centralized web server using a minimization method to receive either intravenous tenecteplase (bolus injection, 0.25 mg/kg; maximum, 25 mg) followed by EVT (n = 166) or EVT alone (n = 164). MAIN OUTCOMES AND MEASURES: The primary outcome was functional independence (modified Rankin Scale score, 0-2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage and 90-day mortality. RESULTS: Among 332 patients randomized, 2 withdrew consent. Of the remaining 330 patients (mean [SD] age, 66 [11] years; 241 males [73%]; 89 females [27%]), 329 completed 90-day follow-up. Of whom, 50 of 165 (30%) in the tenecteplase plus EVT group and 50 of 164 (30%) in the EVT alone group achieved functional independence (adjusted rate ratio, 0.92 [95% CI, 0.67 to 1.25]; risk difference, -0.18% [95% CI, -10.13% to 9.76%]). Symptomatic intracranial hemorrhage occurred in 8 patients (5%) in the tenecteplase plus EVT group and 6 (4%) in the EVT alone group. Mortality at 90 days was similar between the groups (66 [40%] vs 70 [43%], respectively). CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe basilar artery occlusion admitted directly to EVT-capable centers who presented 4.5 to 24 hours after stroke onset, the addition of intravenous tenecteplase before EVT did not result in improved functional outcomes compared with EVT alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05701956.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Li R, Yao X, Nogueira RG, et al. Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial. JAMA. 2026. PMID: 42776543. doi:10.1001/jama.2026.15496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。